[The use of aspirin in patients with primary pulmonary hypertension].
OBJECTIVE
To investigate aspirin efficacy in patients with primary pulmonary hypertension (PPH) after a course of prostaglandin E-1 (PE) treatment.


METHODS
12 PPH patients (mean age 35.7 +/- 2.5 years) having the disease for 6.7 +/- 1.1 years were assigned to a 6-month course of aspirin treatment in a dose 100 mg/day in combination with calcium antagonist isradipin. All the patients have previously undergone 21-day PE treatment (vasaprostan). Before and after the treatment, the patients were examined clinically and biochemically.


RESULTS
As shown by ECG, chest x-ray, bicycle exercise, aspirin used in combination with isradipin led to stabilization of the disease. Platelet aggregation also remained stable, thromboxan B2 and endothelin-1 levels went down. Low doses of aspirin allowed to avoid side effects typical for this drug.


CONCLUSIONS
Use of aspirin in a dose 100 mg/day in combination with calcium antagonists to treat primary pulmonary hypertension is justified.
I E
IE
Chazova
T V
TV
Martyniuk
V P
VP
Masenko
V K
VK
Lazutkina
Iu N
IuN
Belenkov
D000328:Adult; D000527:Alprostadil / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D017275:Isradipine / Q000627:therapeutic use; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013997:Time Factors; D014665:Vasodilator Agents / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D010975:Platelet Aggregation Inhibitors; D014665:Vasodilator Agents; D000527:Alprostadil; D001241:Aspirin; D017275:Isradipine
Primenenie aspirina u bol'nykh s pervichnoĭ legochnoĭ gipertonieĭ.